Mechanisms of HBV Functional Cure During Tenofovir-based ART in HIV/HBV Coinfection
HIV/HBV 合并感染中基于替诺福韦的 ART 期间 HBV 功能性治愈的机制
基本信息
- 批准号:10221470
- 负责人:
- 金额:$ 63.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS clinical trial groupAdultAffectAntibodiesAntigensAntiviral AgentsBiological MarkersCD4 Lymphocyte CountCellsChronicChronic Hepatitis BCircular DNAClinicalClinical ResearchCore BiopsyCountryDNADNA MarkersDevelopmentEpidemiologyFibrosisFine needle aspiration biopsyFundingGenetic TranscriptionGenotypeGoalsHIVHIV InfectionsHIV therapyHepatitis BHepatitis B Surface AntigensHepatitis B VirusHepatocyteImmuneImmune responseImmunityImmunologic FactorsImmunologicsImmunotherapyIndividualInterventionKidneyKineticsLaboratoriesLiverMeasuresMediatingModelingNatural HistoryOutcomePatientsPeripheralPhenotypePopulationPredictive FactorProspective cohortRNAResearchRiskSamplingSerologySurfaceSurrogate MarkersT-LymphocyteTenofovirTestingTherapeuticToxic effectUnited States National Institutes of HealthViralVirusWorkZambiaacute infectionanalogantiretroviral therapybasebonecell typeclinical predictorsco-infectioncohortelastographyexhaustionexperiencegenetic signatureimmune reconstitutionimmunoregulationinhibitor/antagonistintrahepaticliver biopsynovelnovel markernovel therapeuticspredicting responseprogrammed cell death protein 1reconstitutionresponsesingle-cell RNA sequencingviral DNAvirology
项目摘要
PROJECT SUMMARY/ABSTRACT
Chronic hepatitis B virus (HBV) infection, affecting 240 million worldwide including 5-20% of HIV-infected
individuals, results from an inadequate immune response to acute infection and persistence of covalently
closed circular DNA (cccDNA) in the host hepatocyte. During nucleos(t)ide analog therapy for chronic HBV,
`functional cure', the central therapeutic goal defined by loss of hepatitis B surface antigen (HBsAg) with or
without surface antibody development, occurs slowly (~1%/year). There are now a growing number of novel
therapies in development to increase HBV functional cure if not achieve virological cure (i.e., elimination of the
cccDNA reservoir), including agents to restore HBV-specific immunity. Yet, the immune factors critical to
achieving functional cure remain poorly understood because HBsAg loss is usually rare and few studies have
assessed intrahepatic immune responses. To guide the use of novel therapies in HIV-HBV coinfection, a better
understanding is needed of the impact of HIV and HBV-active antiretroviral therapy (ART) on immune control
of HBV. In Zambia, we established a prospective cohort of HIV-HBV coinfected (n=303) and HBV
monoinfected (n=63) adults taking tenofovir (TDF)-based therapies. Within this cohort, which has strong local
laboratory capacity and access to liver sampling, we documented a strikingly high rate (13.1%) of HBsAg loss
among HIV-HBV patients during the first 2 years on TDF-based ART. We now propose to exploit this unique
scientific opportunity to investigate HBV functional cure in HIV infection. Our central hypothesis – that in ART-
treated HIV-HBV coinfection, robust immune reconstitution unleashes an enhanced HBV functional cure
response – will be tested in 3 aims. In Aim 1, using liver fine needle aspirations, we will define the immune
milieu in which HIV-HBV patients experience HBsAg loss/reduction during TDF-based therapy. Phenotypic
responses and single cell RNA-sequencing signatures of T cells and other immune cell types will be compared
by HIV status and CD4 changes during therapy. In Aim 2, we will determine the impact of ART-induced
immune reconstitution in HIV-HBV coinfection on the change in peripheral markers of cccDNA transcription
including quantitative HBsAg and two novel markers, hepatitis B core-related antigens and HBV RNA. In Aim
3, we will define the clinical predictors of HBV functional cure among HIV-HBV coinfected individuals. This
project, which combines translational, clinical, and epidemiological approaches, and leverages an existing NIH-
funded cohort, will lead to a better understanding of (a) the impact of HIV on HBV natural history, (b) how
immunological therapies might work in HIV-HBV coinfection, and (c) whether novel peripheral cccDNA markers
can be used in this population. The proposed research will also advance the broader HBV cure agenda,
including the strategy to combine immune modulation with targeted virological interventions to achieve HBV
functional cure.
项目概要/摘要
慢性乙型肝炎病毒 (HBV) 感染,影响全球 2.4 亿人,其中 5-20% 为 HIV 感染者
个体,由于对急性感染的免疫反应不足和共价键的持续存在而导致
宿主肝细胞中的闭合环状 DNA (cccDNA)。在核苷(酸)类似物治疗慢性乙型肝炎期间,
“功能性治愈”,核心治疗目标是乙型肝炎表面抗原(HBsAg)丧失或
没有表面抗体发育,发生缓慢(~1%/年)。现在小说越来越多
如果没有实现病毒学治愈(即消除
cccDNA 库),包括恢复 HBV 特异性免疫力的药物。然而,免疫因素对
实现功能性治愈仍然知之甚少,因为 HBsAg 消失通常很少见,而且很少有研究表明
评估肝内免疫反应。为了指导 HIV-HBV 合并感染的新疗法的使用,更好的方法
需要了解 HIV 和 HBV 活性抗逆转录病毒治疗 (ART) 对免疫控制的影响
乙肝病毒。在赞比亚,我们建立了 HIV-HBV 合并感染者 (n=303) 和 HBV 的前瞻性队列
接受基于替诺福韦 (TDF) 的治疗的单一感染 (n=63) 成年人。在这个群体中,具有很强的本地化能力
实验室能力和肝脏采样的获取,我们记录了 HBsAg 丢失率惊人的高 (13.1%)
HIV-HBV 患者在接受基于 TDF 的 ART 的头 2 年期间。我们现在建议利用这一独特的
研究 HBV 功能性治愈 HIV 感染的科学机会。我们的中心假设——在 ART 中——
治疗 HIV-HBV 合并感染后,强大的免疫重建可增强 HBV 功能性治愈
响应——将在 3 个目标中进行测试。在目标 1 中,使用肝脏细针穿刺,我们将定义免疫
HIV-HBV 患者在基于 TDF 的治疗期间经历 HBsAg 丢失/减少的环境。表型
将比较 T 细胞和其他免疫细胞类型的反应和单细胞 RNA 测序特征
治疗期间的 HIV 状态和 CD4 变化。在目标 2 中,我们将确定 ART 引起的影响
HIV-HBV合并感染中免疫重建对cccDNA转录外周标志物变化的影响
包括定量 HBsAg 和两种新型标记物:乙型肝炎核心相关抗原和 HBV RNA。瞄准
3,我们将定义 HIV-HBV 共感染个体中 HBV 功能性治愈的临床预测因子。这
该项目结合了转化、临床和流行病学方法,并利用了现有的 NIH-
资助的队列,将导致更好地了解 (a) HIV 对 HBV 自然史的影响,(b) 如何影响
免疫疗法可能对 HIV-HBV 合并感染有效,以及 (c) 新型外周 cccDNA 标记是否有效
可以在这个人群中使用。拟议的研究还将推进更广泛的乙肝治疗议程,
包括将免疫调节与有针对性的病毒学干预措施相结合以实现乙型肝炎的策略
功能性治愈。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Jeffrey Vinikoor其他文献
Michael Jeffrey Vinikoor的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Jeffrey Vinikoor', 18)}}的其他基金
Feasibility of an integrated intervention to reduce advanced HIV disease mortality among hospitalized adults in Zambia
降低赞比亚住院成人晚期艾滋病毒死亡率的综合干预措施的可行性
- 批准号:
10204985 - 财政年份:2019
- 资助金额:
$ 63.86万 - 项目类别:
Mechanisms of HBV Functional Cure During Tenofovir-based ART in HIV/HBV Coinfection
HIV/HBV 合并感染中基于替诺福韦的 ART 期间 HBV 功能性治愈的机制
- 批准号:
10684739 - 财政年份:2019
- 资助金额:
$ 63.86万 - 项目类别:
Feasibility of an integrated intervention to reduce advanced HIV disease mortality among hospitalized adults in Zambia
降低赞比亚住院成人晚期艾滋病毒死亡率的综合干预措施的可行性
- 批准号:
10631322 - 财政年份:2019
- 资助金额:
$ 63.86万 - 项目类别:
Mechanisms of HBV Functional Cure During Tenofovir-based ART in HIV/HBV Coinfection
HIV/HBV 合并感染中基于替诺福韦的 ART 期间 HBV 功能性治愈的机制
- 批准号:
10462553 - 财政年份:2019
- 资助金额:
$ 63.86万 - 项目类别:
Impact of antiretrovial therapy on liver fibrosis in Zambian HIV/HBV patients
抗逆转录病毒治疗对赞比亚 HIV/HBV 患者肝纤维化的影响
- 批准号:
9128155 - 财政年份:2015
- 资助金额:
$ 63.86万 - 项目类别:
Impact of antiretroviral therapy on liver fibrosis in Zambian HIV/HBV patients
抗逆转录病毒治疗对赞比亚 HIV/HBV 患者肝纤维化的影响
- 批准号:
8817006 - 财政年份:2014
- 资助金额:
$ 63.86万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 63.86万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 63.86万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 63.86万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 63.86万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 63.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 63.86万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 63.86万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 63.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 63.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 63.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)